Oruka Therapeutics, Inc. (NASDAQ:ORKA) is VR Adviser LLC's 6th Largest Position

VR Adviser LLC boosted its stake in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 6.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,285,620 shares of the company's stock after acquiring an additional 200,000 shares during the quarter. Oruka Therapeutics comprises 4.4% of VR Adviser LLC's investment portfolio, making the stock its 6th biggest holding. VR Adviser LLC owned 9.39% of Oruka Therapeutics worth $63,708,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. acquired a new stake in Oruka Therapeutics during the 4th quarter worth approximately $54,000. AlphaCentric Advisors LLC acquired a new stake in shares of Oruka Therapeutics in the 4th quarter valued at approximately $119,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Oruka Therapeutics in the 4th quarter valued at approximately $144,000. Squarepoint Ops LLC acquired a new stake in shares of Oruka Therapeutics in the 4th quarter valued at approximately $236,000. Finally, Charles Schwab Investment Management Inc. acquired a new stake in shares of Oruka Therapeutics in the 4th quarter valued at approximately $303,000. 56.44% of the stock is owned by institutional investors and hedge funds.

Oruka Therapeutics Stock Down 2.1%

NASDAQ ORKA traded down $0.24 during mid-day trading on Friday, hitting $10.95. The stock had a trading volume of 135,502 shares, compared to its average volume of 225,915. Oruka Therapeutics, Inc. has a 52-week low of $5.49 and a 52-week high of $31.13. The company has a market cap of $409.98 million, a price-to-earnings ratio of -1.75 and a beta of 0.25. The company has a 50 day simple moving average of $9.79 and a 200 day simple moving average of $14.20.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.17. As a group, equities analysts anticipate that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on ORKA. Wolfe Research began coverage on Oruka Therapeutics in a report on Tuesday, February 4th. They issued an "outperform" rating and a $20.00 price target for the company. HC Wainwright reissued a "buy" rating and issued a $45.00 price target on shares of Oruka Therapeutics in a report on Friday, February 7th. BTIG Research began coverage on Oruka Therapeutics in a report on Thursday. They issued a "buy" rating for the company. Wall Street Zen raised Oruka Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday. Finally, Wedbush reissued an "outperform" rating and issued a $40.00 price target on shares of Oruka Therapeutics in a report on Thursday, May 15th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Oruka Therapeutics presently has an average rating of "Buy" and an average target price of $40.38.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.